manifestations. The biochemical defect in PNH resides in the incomplete enzymatic assembly of glycosylphosphatidylinositol (GPI) anchors used for surface protein attachment. In all patients tested thus far, the defect is at the level of N-acetylglucosamine attachment to phosphatidylinositol (complementation class A defect). A human cDNA, Piga, that repairs cell lines with the class A defect has been recently cloned, making Piga a candidata gene for PNH. In the current AROXYSMAL NOCTURNAL hemoglobinuria (PNH) is an acquired clonal hematologic disorder with protean clinical manifestations, including erythrocyte hemolysis, venous thrombosis, infections, and defective hematopoiesis.'.' The primary biochemical defect in PNH resides in the incomplete synthesis of glycosylphosphatidylinositol (GPI) anchors used to attach certain proteins to the cell ~u r f a c e .~'~ In PNH, there is a deficiency of all GPI-linked surface proteins on the abnormal clone of hematopoietic cells, with clinical manifestations resulting from the absence of these proteins. In all patients tested to date, the defect occurs at the level of N-acetyl-glucosamine addition to the phosphatidylinositol acceptor molecule, an early step in GP1 anchor biosynthesi^.'.^ Using the nomenclature of GPI-deficient murine cell lines," all PNH patients have a class A complementation defect. ' Miyata et a l l ' recently cloned the Piga cDNA, which repairs the class A defect in a human GPI-deficient cell line. Named for its ability to repair a phosphatidylinositol glycan class A defect, Piga is a candidate gene for PNH. Genetic mutations within the Piga gene could cause incomplete GP1 anchor biosynthesis and abnormal expression of all GPIlinked surface proteins. Recently, a nucleotide deletion leading to a splicing defect in the Piga gene was reported in an Epstein-Barr virus (EBV)-transformed cell line derived from a patient with PNH, and confirmed in the patient's peripheral blood neutrophils.'' Using highly purified GPI-deficient granulocytes as a source of RNA, we have performed total RNA (Northern blot) and reverse transcriptase polymerase chain reaction (RT-PCR) analysis of Piga in four patients with PNH. In each case, we have identified a mutation within the Piga coding sequence. In two of the patients, a frameshift mutation in the 5' coding region results in an early termination codon, whereas in a third patient a similar frameshift mutation is present in the 3' coding region. The abnormal granulocytes in these three patients are completely deficient in surface expression of GPI-linked proteins, consistent with a mutation that causes complete loss of function. In contrast, the fourth patient has a missense mutation in the Piga coding region, leading to a single amino acid substitution. The abnormal granulocytes of this patient have dim expression of GPI-linked proteins, consistent with a mutation that only partially abrogates function. Our results provide direct evidence that mutations within the Piga gene are responsible for PNH, and offer preliminary insight into structure/function relationships of the Piga molecule.
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(RT-PCR) analysis of Piga in four patients with PNH. In each case, we have identified a mutation within the Piga coding sequence. In two of the patients, a frameshift mutation in the 5' coding region results in an early termination codon, whereas in a third patient a similar frameshift mutation is present in the 3' coding region. The abnormal granulocytes in these three patients are completely deficient in surface expression of GPI-linked proteins, consistent with a mutation that causes complete loss of function. In contrast, the fourth patient has a missense mutation in the Piga coding region, leading to a single amino acid substitution. The abnormal granulocytes of this patient have dim expression of GPI-linked proteins, consistent with a mutation that only partially abrogates function. Our results provide direct evidence that mutations within the Piga gene are responsible for PNH, and offer preliminary insight into structure/function relationships of the Piga molecule.
MATERIALS AND METHODS
Isolation andpurijcation of GPI-deficient granulocytes. Peripheral venous blood was collected in EDTA from patients with PNH in accordance with a protocol approved by the Duke University Medical Center Institutional Review Board. Granulocytes were isolated using a Ficoll-Hypaque density gradient (Ficoll, Sigma, St Louis, MO; Hypaque, Winthrop, New York, NY) to remove mononuclear cells, followed by dextran agglutination of erythrocytes: Normal GPI-positive granulocytes were removed using a CD59 monoclonal antibody (MoAb) and magnetic bead selection technique as previously described? Immunophenotypic analysis by flow cytometry documented enrichment of the abnormal GPI-deficient granulocytes to approximately 99% purity.
Northern blot analysis. The highly purified GPI-deficient granulocytes were lysed in 4 m o m guanidinium buffer, and total RNA was isolated using a cesium chloride centrifugation meth0d.l3 Northern analysis was performed as de~cribed,'~ using 8.0 pg total RNA in each lane. Random labeled Piga probe was hybridized using QuickI-Iyb (Stratagene, La Jolla, CA). RNA blots were washed first in 2 x SSC with 0.1% sodium dodecyl sulfate (SDS) and 1 mmoV L EDTA for 15 minutes at room temperature, then with a higher stringency wash of 0.5X SSC with 0.1% SDS and 1 mmom EDTA at 58°C for 30 minutes, followed by radiographic exposure at -70°C.
RT reaction. Total RNA from GPI-deficient granulocytes (1.0 pg) was used as a template in an RT reaction to generate cDNA. f'rinwr.s. Oligonucleotide primers were synthesized according to the published Pi,qrr cDNA sequence," and collectively spanned the entire Pigtr coding region. The nucleotide sequences and location of each primer pair arc as follows: S'GGGGAATTCGAG-GACACATCTCTTAACTGG3' (nucleotides 30 through SO) with S'GTATCACAAAGAGACACGG3' (61 8 through 600): S'GG-ACCATTCCCTTTTTGGA3' (421 through 442) with S'CCTT-TTCCAATCCTTCACA3' ( I 169 through 1 IS I ): and S'CCA-GAGTTGGTGGAATTCCTGAG3' (IO77 through 1099) with S'CCTGGTTTCAGATATCTCA3' ( IS37 through 1519) . The location of each primer is listed according to the numbering system used in the published sequence of P i p / cDNA." When possible. primers were chosen near a unique restriction endonuclease (RE) site. to facilitate cloning of PCR products. The lirst primer. which begins S6 bp upstream of the ATG translation initiation site. has a S' EcoR1 site incorporated into its sequence.
PCR. A SO pL PCR reaction. which contained 1.0 pL of the RT reaction as a source of template cDNA. I pg of each primer. 2.5 U of Trq polynierase (Stratagene). IO nmol of dNTPs. S pL I O X reaction buffer (Stratagene). and ddH20. The reaction mixture was heated to 94°C for 3 minutes for initial denaturation. followed by 35 cycles of 94°C for I minute. S I T for 2 minutes. and 72°C for 2 minutes. Eech PCR product was purified using Prep-a-gene (Biorad. Richmond. CA) hefore RE digestion. then purified again before ligation. Bluescript vector (Stratagene) was cut with the appropriate RE. and ligation was performed in a 2O-pL reaction containing T4 ligase. adenosine triphosphate. and IOX ligase buffer (Pharmacia). The ligated product was transformed into TG-I bacteria. and positive colonies were tirst identified using blue-white 8-galactosidase selection. and then confirmed by PCR using Ranking T3 and T7 primers. Individual clones that contained inserts of the correct size were then grown overnight in a IO-mL culture. and the amplilied plasmids were puritied using Magicprep (Promega) and chemically denatured. Double-stranded sequencing reactions were performed in both directions. using the T3 and T7 primers as well as internal primers. with the Sequenase 11 sequencing kit (US Biochemical. Cleveland. OH ): sequencing gels were 6% acrylamide and run at 47°C. When a potential mutation was identified by sequence analysis. additional clones were sequenced for confirmation. By flow cytometry, the abnormal GPI-deficient granulocytes of three patients (UPN 166, 261, and 267) were completely deficient in surface expression of CD59 (Fig IA) . However, UPN I 15 had partially deficient granulocytes with dim surface expression of CD59 (Fig I B) . Granulocytes from a normal volunteer had bright surface expression of CD59 (Fig IC) .
RESULTS
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Northern blot analysis. Total RNA obtained from purified GPI-deficient granulocytes was electrophoresed and probed for expression of Piga mRNA. Figure 2 shows a Northern blot of RNA from three patients, and in each case demonstrates a single Piga mRNA band of normal size and intensity. This result suggested that mutations within the Piga gene would likely be small insertions, deletions, or point mutations that did not lead to unstable or truncated Sequence analysis of Piga. After RT-PCR and subcloning of PCR products, the complete coding region of Piga cDNA was sequenced for each patient, and a different mutation was identified in each case. In three patients, a frameshift mutation was identified, whereas one patient had a missense mutation in Pigo. For patient I (UPN 267). a two-nucleotide (GT) insertion was found at position 334 (Fig 3A) , leading to a premature termination codon (TGA) at position 370. Similarly, in patient 2 (UPN 261) a single nucleotide (C) deletion at position 516 was identified (Fig 3B) . This frameshift mutation leads to a premature termination codon (TAA) at position 598. In patient 3 (UPN 166), a two-nucleotide (CT) deletion at position 1408 was identified (Fig 3C) , leading to a termination codon (TGA) at position 1438. In contrast, a single-nucleotide substitution, A to G at position 974, was identified in patient 4 (UPN 115, Fig 3D) . This missense mutation changes the codon AAT to GAT, and
therefore alters the predicted amino acid translation from asparagine (N) to aspartic acid (D).
DISCUSSION
The Piga gene has been localized to the short arm of human X chromosome at the Xp22.1 region, using fluorescent in situ hybridization'* and genetic mapping techniques." In contrast, Pigfand Pigh, two other genes involved in the biosynthesis of the GP1 anchor, map to autosomes in both mouse and human^.'^ These results help explain the predominance of the class A defect in PNH, and also explain why males and females are equally affected by the disorder. Due to random inactivation of the X chromosome, only one Piga gene is active in the hematopoietic cells of females. Accordingly, a single mutation in Piga could disrupt GP1 anchor biosynthesis and lead to a deficiency of all GPI-linked proteins and PNH in either sex. However, because PNH is characterized by an abnormal clone of hematopoietic cells that coexists with normal blood cells,'"." molecular analysis of this disorder requires either selective purification or proliferation of the GPI-deficient cells. EBV-transformed B-lymphocyte lines or short-term GPI-deficient T-lymphocyte lines can be derived from some PNH patient^,"'.^.'^ but circulating lymphocytes are not frequently affected at a high percentage, and the stimulation/ transformation of cells might introduce artifacts. Therefore, we directly analyzed GPI-deficient granulocytes from PNH patients, as the majority of these circulating cells often have abnormal surface expression of GPI-linked proteins. After a short purification procedure, we directly purified RNA for Northern blot and RT-PCR analysis of P i p .
Our identification of distinct mutations within the Piga coding sequence in four patients with PNH provides convincing evidence that alterations in the Piga gene are responsible for this hematologic disorder. In three patients (UPN 166, 261, and 267), frameshift mutations within the coding sequence were identified, each of which would lead to a premature termination codon. The abnormal PNH erythrocytes and granulocytes in these three patients were exclusively type 111 cells, indicating a complete deficiency in GP1 anchor biosynthesis and absence of GPI-linked surface proteins. In each of these three patients, a normal amount of Piga mRNA was present in GPI-deficient granulocytes by Northern analysis, indicating that the stability of the Piga mRNA is unaffected by the mutations. For the two patients with frameshift mutations in the 5' region of the coding sequence (UPN 267 and 261), the resulting truncated protein would likely be unstable andor be unable to function properly. In contrast, the frameshift mutation in UPN 166 would lead to termination at nucleotide position 1438, which is relatively close to the wildtype termination codon (TAG) at 1540. The predicted amino acid sequence for this mutation diverges from the wildtype at nucleotide position 1408, which normally encodes for leucine (L), the last amino acid residue in the predicted endoplasmic reticulum transmembrane region of the Piga protein. Instead of leucine followed by the presumed intraluminal domain of 42 amino acid residues, this mutation would encode for glutamic acid (E) followed by only an additional 8 residues. Thus, this mutation may yield a Piga protein product that cannot fold correctly, cannot insert correctly into the ER membrane, or lacks important sequences at the C-terminus leading to a complete loss of function.
The A to G point mutation in UPN 115 at position 974 changes the codon AAT to GAT, and leads to the substitution of aspartic acid (D) for the wildtype asparagine (N). This mutation, which changes a neutral residue to an acidic residue, presumably has a deleterious effect on either the proper folding, function, or stability of the Piga protein. Because this patient has a population of type I1 erythrocytes, and granulocytes that have partial expression of GPI-linked proteins (Fig lB) , we assume that this mutant Piga protein has partial function. At present, we cannot comment further on the nature of the Piga protein product in this mutation, because of the lack of antisera that can identify the Piga molecule. However, we speculate that all PNH patients with type 11 cells will have missense P i p mutations with partial protein function.
Our observations also provide initial insight into the understanding of the structure/function relationships of the Piga protein. Identification of other mutations, especially point (missense) mutations, in PNH patients will provide additional information regarding active and important sites of the Piga protein.
NOTE ADDED IN PROOF
Bessler et ally and Miyata et al'" recently reported mutations in the Piga gene in patients with PNH.
